A Novel Serum Based Biomarker Panel Has Complementary Ability To Preclude Presence Of Early Lung Cancer For Low Dose Ct (Ldct)
Xiaobing Wang,Xiuyi Zhi,Zhaogang Yang,Haimei Tian,Yanfen Li,Mo Li,Wenya Zhao,Chao Zhang,Teng Wang,Jing Liu,Di Shen,Cuining Zheng,Dan Zhao,Sheng Yang,Jun Qi,Hongwu Xin,Alexander Stojadinovic,Itzhak Avital,L James Lee,Jianyu Rao,Wei Zhang
DOI: https://doi.org/10.18632/oncotarget.17477
2017-01-01
Oncotarget
Abstract:Low Dosage Computerized Tomography (LDCT) has been shown to improve early detection of lung cancer and mortality rates in high-risk individuals, which was, however, limited by specifically coverage for heavy smokers and high rates of false positivity. Here, we aim to investigate a novel biomarker for early detection of lung cancer, and further extend to concentrate high-risk subjects for increasing specificity and coverage of LDCT. We performed retrospective blinded evaluation of lung cancer and healthy controls in training and validation cohorts. Macrophage inhibitory cytokine 1 (MIC-1) alone and panel were assessed. Our data showed the sensitivity of MIC-1 was 72.2% and 67.1% for lung cancer diagnosis and early diagnosis respectively, at 96.6% specificity, which were significantly higher than Cyfra21-1, NSE CA125, CEA and SCC. At 90% specificity, the panel of MIC-1, Cyfra21-1, CA125 and CEA provided 89.5% sensitivity for early diagnosis of lung cancer, which could be used to concentrate the high-risk subjects for further LDCT screening. We conclude that MIC-1 have great capacity in early lung cancer diagnosis. The algorithmic panel of MIC-1, Cyfra21-1, CA125 and CEA could be used to refine the preselection criteria of high-risk subjects, and thus might facilitate the widespread implementation of LDCT screening.